GlobeNewsWire
17 Nov 2026, 13:45 UTC · 1h ago
MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer
Impact · against what's priced in
MAIA Biotechnology's stock faces a positive catalyst as updated Phase 2 data for THIO-101 demonstrates consistent efficacy in NSCLC. The potential for an accelerated approval filing significantly advances the expected commercialization timeline.
- MAIA+0.60
No priced-in read yet





